Osilodrostat: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted osilodrostat, while AWMSG (Wales) and NYE METODER (Norway) did not recommend it.
On the same population the two systems disagree outright: PBAC (Australia) recorded recommended for “Cushing syndrome”, while AWMSG (Wales) recorded not recommended for “Treatment of endogenous Cushing’s syndrome in adults”.
The record spans 4.9 years, opening at AWMSG (Wales) on 15 Sep 2020 and running to 7 Aug 2025.
PBAC (Australia) changed its position: not recommended in 2023, recommended by 2024, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
Not every gap is a refusal: for osilodrostat, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 5 of 14 records date from 2023 or later.
3 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess osilodrostat, on 15 Sep 2020; HIRA (South Korea) did not open a file until 7 Aug 2025 — a wide spread of 4.9 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 14 dated records fall in 2021 alone.
2 of the 11 agencies here assessed osilodrostat more than once, PBAC (Australia) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for osilodrostat.
The full ledger for osilodrostat reads 6 recommended, 5 not recommended, 1 non-submission and 1 advice, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HIRA (South Korea) | 7 Aug 2025 | 뇌하수체 수술이 불가능하거나 , 수술 후 충분한 효과를 얻지 못한 성인 쿠싱병 환자의 치료 | reimbursement appropriate | source |
| PBAC (Australia) | 2024 | Cushing syndrome (CS) | Not Recommended | source |
| SMC (Scotland) | 11 Dec 2023 | For treatment of endogenous Cushing’s syndrome in adults. | not recommended | source |
| DMC (Denmark) | 14 Dec 2022 | Behandling af endogen Cushings syndrom hos voksne | Anbefalet | source |
| CIPM (Spain) | 3 Mar 2022 | Indicaciones terapéuticas autorizadas: Isturisa está indicado para el tratamiento del síndrome de Cushing endógeno en ad… | financed by the SNS, on appeal · art. 92 a, c | source |
9 further decisions for osilodrostat, across 8 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- ketoconazole — same ATC class H02C — Systemic corticosteroids
- tremelimumab — also decided by HIRA in 2025Q3
- durvalumab — also decided by HIRA in 2025Q3
- treprostinil — also decided by HIRA in 2025Q3
- odevixibat — also decided by HIRA in 2025Q3
- cefiderocol — also decided by HIRA in 2025Q3
Coverage: 14 decisions for osilodrostat from 11 agencies, 2020 to 2025. Data to 7 Sep 2026. ATC class H02C — Systemic corticosteroids. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.